Dasatinib

Product NDC
72205-324
Requested package NDC
72205-324-30
11-digit product format
722050324
Labeler code
72205
Product ID
72205-324_bffb38c3-f556-492f-a9db-aa417ec0a856
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Dasatinib
Dosage form
TABLET
Route
ORAL
Labeler
Novadoz Pharmaceuticals LLC
Application
ANDA219579
Marketing category
ANDA
Marketing start
2026-09-11
Substance
DASATINIB
Active strength
140 mg/1
Pharmacologic classes
Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 6 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A219579-001DASATINIBDASATINIB20MGTABLET / ORALAB2026-09-11
A219579-002DASATINIBDASATINIB50MGTABLET / ORALAB2026-09-11
A219579-003DASATINIBDASATINIB70MGTABLET / ORALAB2026-09-11
A219579-004DASATINIBDASATINIB80MGTABLET / ORALAB2026-09-11
A219579-005DASATINIBDASATINIB100MGTABLET / ORALAB2026-09-11
A219579-006DASATINIBDASATINIB140MGTABLET / ORALAB2026-09-11

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 6 matching rows.

Application-product, TE code table
Application-productTE code
A219579-001AB
A219579-002AB
A219579-003AB
A219579-004AB
A219579-005AB
A219579-006AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A219579-001DASATINIB20MGTABLET / ORALAB2026-09-11d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-002DASATINIB50MGTABLET / ORALAB2026-09-11d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-003DASATINIB70MGTABLET / ORALAB2026-09-11d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-004DASATINIB80MGTABLET / ORALAB2026-09-11d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-005DASATINIB100MGTABLET / ORALAB2026-09-11d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-006DASATINIB140MGTABLET / ORALAB2026-09-11d4dbc9d85df4…
2026-10-15 13:18:302026-09A219579-001DASATINIB20MGTABLET / ORALAB2026-09-11c2088c7a36db…
2026-10-15 13:18:302026-09A219579-002DASATINIB50MGTABLET / ORALAB2026-09-11c2088c7a36db…
2026-10-15 13:18:302026-09A219579-003DASATINIB70MGTABLET / ORALAB2026-09-11c2088c7a36db…
2026-10-15 13:18:302026-09A219579-004DASATINIB80MGTABLET / ORALAB2026-09-11c2088c7a36db…
2026-10-15 13:18:302026-09A219579-005DASATINIB100MGTABLET / ORALAB2026-09-11c2088c7a36db…
2026-10-15 13:18:302026-09A219579-006DASATINIB140MGTABLET / ORALAB2026-09-11c2088c7a36db…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A219579-001AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-002AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-003AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-004AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-005AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A219579-006AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A219579-001AB1c2088c7a36db…
2026-10-15 13:18:302026-09A219579-002AB1c2088c7a36db…
2026-10-15 13:18:302026-09A219579-003AB1c2088c7a36db…
2026-10-15 13:18:302026-09A219579-004AB1c2088c7a36db…
2026-10-15 13:18:302026-09A219579-005AB1c2088c7a36db…
2026-10-15 13:18:302026-09A219579-006AB1c2088c7a36db…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product
Yes
Brand name base
Dasatinib
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
DASATINIB140 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
RBZ1571X5HInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 6 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
643105Internal RxNorm lookup
643107Internal RxNorm lookup
643109Internal RxNorm lookup
799047Internal RxNorm lookup
1045402Internal RxNorm lookup
1045406Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
bffb38c3-f556-492f-a9db-aa417ec0a856Available on FDA.report

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
DasatinibDASATINIBNovadoz Pharmaceuticals LLCbffb38c3-f556-492f-a9db-aa417ec0a8562024-10-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 219579
application number: ANDA219579
ndc (package): 72205-324-30
ndc (product): 72205-324
ndc11 (package): 72205032430

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startSampleExclude flagStatus
72205-324-307220503243030 TABLET in 1 BOTTLE (72205-324-30) 30 tablet2026-09-11NoNoCurrent